Genetic (shRNA and siRNA) and pharmacological (BAY1217389 and CFI-402257) inhibition of TTK suppressed proliferation and enhanced chemosensitization in ovarian cancer cells (Figs. 2–5). The gene discussed is TTK; the disease is ovarian carcinoma.